{"config":{"lang":["en"],"separator":"[\\s\\-]+","pipeline":["stopWordFilter"],"fields":{"title":{"boost":1000.0},"text":{"boost":1.0},"tags":{"boost":1000000.0}}},"docs":[{"location":"","title":"Imaging Guidelines &amp; Decision Tools","text":"<p>Purpose</p> <p>Evidence-based imaging guidelines and reporting standards used at our institution. Last Updated: February 2024</p>"},{"location":"#quick-access-by-category","title":"Quick Access by Category","text":"<ul> <li> <p> Pulmonary</p> <p>Fleischner Society Incidental pulmonary nodules</p> <p> View</p> <p>Lung-RADS Lung cancer screening</p> <p> View</p> </li> <li> <p> Abdominal - Liver &amp; Biliary</p> <p>LI-RADS Liver imaging reporting</p> <p> View</p> <p>Liver Lesion Workup Diagnostic algorithm</p> <p> View</p> </li> <li> <p> Abdominal - Renal &amp; Adrenal</p> <p>Renal Lesions Characterization &amp; Management</p> <p> View</p> <p>Adrenal Nodules Workup &amp; Washout</p> <p> View</p> </li> <li> <p> Gynecology</p> <p>Adnexal Masses Ultrasound evaluation</p> <p> View</p> <p>Early Pregnancy Viability &amp; Unknown Location</p> <p> View</p> </li> <li> <p> Thyroid</p> <p>Thyroid Nodules Ultrasound &amp; Biopsy criteria</p> <p> View</p> </li> <li> <p> Neuro &amp; MSK</p> <p>Pituitary Incidental findings</p> <p> View</p> <p>Scoliosis Imaging guidelines</p> <p> View</p> </li> </ul>"},{"location":"#complete-guideline-index","title":"Complete Guideline Index","text":""},{"location":"#pulmonary","title":"Pulmonary","text":"Guideline Topic Link Fleischner Society 2017 Incidental Nodules View Lung-RADS Lung Cancer Screening View TN Lung Cancer Staging Staging View"},{"location":"#abdominal-liver-pancreas-gi","title":"Abdominal - Liver, Pancreas, GI","text":"Guideline Topic Link LI-RADS HCC Screening/Diagnosis View Liver Lesion Workup General approach View Hepatic Trauma Injury Grading View Pancreatic Cysts Incidental Cysts View Pancreatic Injury Trauma Grading View Rectal Cancer Staging/Reporting View Gallbladder/Biliary General View Splenic Injury Trauma Grading View"},{"location":"#abdominal-renal-adrenal","title":"Abdominal - Renal &amp; Adrenal","text":"Guideline Topic Link Renal Lesion Management Cystic &amp; Solid Masses View Renal Injury Trauma Grading View Adrenal Nodule Workup View Adrenal Washout Calculator/Method View"},{"location":"#gynecology","title":"Gynecology","text":"Guideline Topic Link Adnexal Mass Workup View Adnexal Cysts Ultrasound Follow-up View Early Pregnancy Initial Viability View Pregnancy Follow-up Viability Follow-up View Unknown Location Pregnancy of Unknown Location View"},{"location":"#vascular","title":"Vascular","text":"Guideline Topic Link Abdominal Aortic Aneurysm Surveillance &amp; Reporting View"},{"location":"#thyroid-headneck","title":"Thyroid &amp; Head/Neck","text":"Guideline Topic Link Thyroid Nodule General Management View Thyroid Ultrasound US Features &amp; Reporting View"},{"location":"#neuro-msk","title":"Neuro &amp; MSK","text":"Guideline Topic Link Pituitary Incidental Findings View Scoliosis Imaging Protocol View"},{"location":"#contributing","title":"Contributing","text":"<p>Suggest a Guideline</p> <p>Have a guideline you'd like added? Contact the Radiology QI Committee.</p> <p>Email: radiology_qi@institution.edu</p> <p>Maintained by: Radiology Quality Improvement Committee</p>"},{"location":"pulmonary/fleischner/","title":"Fleischner Society Guidelines for Incidental Pulmonary Nodules","text":"Reference Information <p>Full Citation: MacMahon H, Naidich DP, Goo JM, et al. Guidelines for Management of Incidental Pulmonary Nodules Detected on CT Images: From the Fleischner Society 2017. Radiology. 2017;284(1):228-243. Version: 2017 Update Last Institutional Review: January 2024 Modifications: None - following published guidelines exactly  </p>"},{"location":"pulmonary/fleischner/#quick-reference-tables","title":"Quick Reference Tables","text":"Solid nodulesSubsolid nodules Nodule type Risk \u22646 mm 6\u20138 mm &gt;8 mm Comments Single Low Risk No routine follow-up CT 6\u201312 mo; consider CT 18\u201324 mo Consider CT ~3 mo, PET/CT and/or biopsy Consider 12 mo FU in selected suspicious nodules Single High Risk Optional CT at 12 mo CT 6\u201312 mo and CT 18\u201324 mo Consider CT ~3 mo, PET/CT and/or biopsy Higher concern with suspicious morphology / upper lobe, etc. Multiple Low Risk No routine follow-up CT 3\u20136 mo; consider CT 18\u201324 mo CT 3\u20136 mo \u00b1 PET/CT/biopsy Base management on most suspicious nodule Multiple High Risk Optional CT at 12 mo CT 3\u20136 mo and CT 18\u201324 mo CT 3\u20136 mo \u00b1 PET/CT/biopsy Base management on most suspicious nodule <p>Perifissural note: If a nodule is perifissural with a polygonal shape (typical intrapulmonary lymph node), no follow-up is required.</p> Nodule type Pattern &lt;6 mm \u22656 mm Comments Single Ground-glass No routine follow-up CT 6\u201312 mo to confirm persistence, then q2y until 5y Consider longer follow-up if suspicious Single Part-solid No routine follow-up CT 3\u20136 mo to confirm persistence; if persistent, annual CT until 5y (manage by solid component) Persistent part-solid often higher risk Multiple Ground-glass CT 3\u20136 mo; if stable, consider CT at 2 and 4y CT 3\u20136 mo; subsequent management guided by most suspicious nodule Follow most suspicious nodule Multiple Part-solid CT 3\u20136 mo; if stable, consider CT at 2 and 4y CT 3\u20136 mo; subsequent management guided by most suspicious nodule Follow most suspicious nodule"},{"location":"pulmonary/fleischner/#risk-criteria","title":"Risk Criteria","text":"<ul> <li> <p>Low Risk Criteria</p> <ul> <li>Minimal or absent smoking history</li> <li>No other risk factors</li> </ul> </li> <li> <p>High Risk Criteria</p> <ul> <li>Current or former smoker</li> <li>Family history of lung cancer  </li> <li>Radon or asbestos exposure</li> <li>Age &gt;50 years</li> <li>COPD or pulmonary fibrosis</li> </ul> </li> </ul> How to Measure Nodules <p>Solid Nodules:</p> <ul> <li>Measure longest diameter in axial plane</li> <li>Use lung windows (W: 1500, L: -600)</li> <li>Average diameter if growth assessment needed</li> </ul> <p>Part-Solid Nodules:</p> <ul> <li>Measure total diameter (entire nodule)</li> <li>Measure solid component separately</li> <li>Solid component determines management</li> </ul> <p>Ground Glass Nodules:</p> <ul> <li>Measure longest diameter</li> <li>Volume measurement preferred when available</li> </ul> <p>Preferred Method:</p> <ul> <li>Semi-automated volumetry when available</li> <li>Volume doubling time (VDT) for growth assessment</li> </ul>"},{"location":"pulmonary/fleischner/#when-to-use-lung-rads-instead","title":"When to Use Lung-RADS Instead","text":"<p>Use Lung-RADS for Screening Exams</p> <p>These Fleischner guidelines apply to incidental nodules found on CT performed for other reasons.</p> <p>For lung cancer screening CTs, use Lung-RADS instead.</p>"},{"location":"pulmonary/fleischner/#related-content","title":"Related Content","text":""},{"location":"pulmonary/fleischner/#related-protocols","title":"Related Protocols","text":"<ul> <li>Chest CT Nodule Follow-up Protocol</li> </ul>"},{"location":"pulmonary/fleischner/#related-guidelines","title":"Related Guidelines","text":"<ul> <li>Lung-RADS v1.1 - For lung cancer screening</li> <li>Brock Model - Nodule malignancy risk calculator</li> </ul>"},{"location":"pulmonary/fleischner/#external-resources","title":"External Resources","text":"<ul> <li>Original Publication (Radiology)</li> <li>Fleischner Society Website</li> </ul>"},{"location":"pulmonary/fleischner_clickable/","title":"Pulmonary Nodule 2017 Clickable Image","text":"<p>Original Guideline</p> <p>:octicons-file-pdf-24: Download Original PDF</p>"},{"location":"pulmonary/fleischner_clickable/#reference-images","title":"Reference Images","text":""},{"location":"pulmonary/lung_cancer_staging/","title":"Lung Cancer Staging","text":"<p>No PDF Available</p> <p>The original PDF for this guideline could not be found.</p>"},{"location":"pulmonary/lung_cancer_staging/#reference-images","title":"Reference Images","text":""},{"location":"pulmonary/lung_rads/","title":"Lung-RADS\u2122 v1.1 - Lung Cancer Screening Reporting","text":"Reference Information <p>Full Name: Lung CT Screening Reporting &amp; Data System Version: 1.1 (2019) Publisher: American College of Radiology (ACR) Application: Annual low-dose CT lung cancer screening Last Institutional Review: January 2024 Modifications: None</p> Lung-RADS Quick Reference Category Finding Management Malignancy Risk Lung-RADS 0 Incomplete Additional imaging needed N/A Lung-RADS 1 Negative Continue annual screening &lt;1% Lung-RADS 2 Benign Continue annual screening &lt;1% Lung-RADS 3 Probably benign 6-month follow-up CT 1-2% Lung-RADS 4A Suspicious 3-month follow-up CT 5-15% Lung-RADS 4B Very suspicious 3-month PET/CT or tissue sampling &gt;15% Lung-RADS 4X Category 3 or 4 + additional findings See category 3 or 4 management Variable"},{"location":"pulmonary/lung_rads/#detailed-classification","title":"Detailed Classification","text":"<ul> <li> <p>Category 0: Incomplete</p> <p>Additional Imaging Needed</p> <p>Reasons for Category 0:</p> <ul> <li>Prior CT needed for comparison</li> <li>Technically inadequate study</li> <li>Additional imaging recommended (e.g., dedicated chest CT for findings on non-screening CT)</li> </ul> <p>Management: Complete imaging before final classification</p> </li> <li> <p>Category 1: Negative</p> <p>No Nodules - Annual Screening</p> <p>Findings:</p> <ul> <li>No lung nodules</li> <li>Definitely benign nodules only (completely calcified, fat-containing)</li> </ul> <p>Management: Continue annual LDCT screening in 12 months</p> <p>Malignancy Risk: &lt;1%</p> </li> <li> <p>Category 2: Benign Appearance or Behavior</p> <p>Benign - Annual Screening</p> <p>Nodules with specific benign features:</p> <ul> <li>Perifissural or perivascular nodules &lt;10 mm</li> <li>Completely or centrally calcified nodules</li> <li>Fat-containing nodules</li> </ul> <p>Size criteria (no suspicious features):</p> <ul> <li>Solid: &lt;6 mm average diameter</li> <li>Part-solid: &lt;6 mm total diameter  </li> <li>Ground glass (non-solid): &lt;30 mm</li> </ul> <p>Management: Continue annual LDCT in 12 months</p> <p>Malignancy Risk: &lt;1%</p> </li> <li> <p>Category 3: Probably Benign</p> <p>Short-Term Follow-Up Recommended</p> <p>Solid nodules:</p> <ul> <li>\u22656 to &lt;8 mm average diameter</li> </ul> <p>Part-solid nodules:</p> <ul> <li>\u22656 mm total diameter with solid component &lt;6 mm</li> </ul> <p>Ground glass (non-solid):</p> <ul> <li>\u226530 mm</li> </ul> <p>New nodules (compared to prior):</p> <ul> <li>&lt;4 mm</li> </ul> <p>Management: 6-month LDCT</p> <p>Malignancy Risk: 1-2%</p> </li> <li> <p>Category 4A: Suspicious</p> <p>Suspicious - Consider PET/CT or Biopsy</p> <p>Solid nodules:</p> <ul> <li>\u22658 to &lt;15 mm average diameter</li> </ul> <p>Part-solid nodules:</p> <ul> <li>\u22656 mm total diameter with solid component \u22656 to &lt;8 mm</li> </ul> <p>Ground glass (non-solid):</p> <ul> <li>No specific size criteria (determined by radiologist judgment)</li> </ul> <p>New nodules:</p> <ul> <li>\u22654 to &lt;6 mm</li> </ul> <p>Management: 3-month LDCT</p> <p>Malignancy Risk: 5-15%</p> </li> <li> <p>Category 4B: Very Suspicious</p> <p>Very Suspicious - PET/CT, Tissue Sampling, or Surgical Consultation</p> <p>Solid nodules:</p> <ul> <li>\u226515 mm average diameter</li> </ul> <p>Part-solid nodules:</p> <ul> <li>\u22656 mm total diameter with solid component \u22658 mm</li> </ul> <p>Ground glass (non-solid):</p> <ul> <li>No specific size criteria (determined by radiologist judgment)</li> </ul> <p>New nodules:</p> <ul> <li>\u22656 mm</li> </ul> <p>Category 3 or 4A nodules with growth:</p> <ul> <li>Growth on interval imaging</li> </ul> <p>Management: Chest CT with or without contrast, PET/CT, and/or tissue sampling depending on probability of malignancy and comorbidities</p> <p>Malignancy Risk: &gt;15%</p> </li> <li> <p>Category 4X: Additional Suspicious Features</p> <p>Category 3 or 4 + Clinically Significant Findings</p> <p>Applies when Category 3 or 4 nodule PLUS:</p> <ul> <li>Lymphadenopathy suspicious for lung cancer</li> <li>Suspicious lung mass/nodule features (spiculation, cavity)</li> <li>Endobronchial lesion</li> </ul> <p>Management: Consider chest CT with contrast, PET/CT, and/or tissue sampling</p> <p>Malignancy Risk: Variable (based on underlying category + additional features)</p> </li> </ul>"},{"location":"pulmonary/lung_rads/#measurement-guidelines","title":"Measurement Guidelines","text":"How to Measure - Lung-RADS Specific <p>Solid Nodules:</p> <ul> <li>Measure average diameter: (longest diameter + perpendicular diameter) \u00f7 2</li> <li>Use lung windows (W: 1500, L: -600)</li> <li>Round to nearest whole millimeter</li> </ul> <p>Part-Solid Nodules:</p> <ul> <li>Measure total diameter (entire nodule including ground glass)</li> <li>Measure solid component separately using average diameter</li> <li>Solid component determines category</li> </ul> <p>Ground Glass (Non-Solid) Nodules:</p> <ul> <li>Measure average diameter</li> <li>Must obscure vessels but no solid component</li> </ul> <p>Multiple Nodules:</p> <ul> <li>Classify based on most suspicious nodule</li> <li>Report up to 3 most significant nodules</li> </ul>"},{"location":"pulmonary/lung_rads/#special-modifiers","title":"Special Modifiers","text":""},{"location":"pulmonary/lung_rads/#s-modifier-significant-or-potentially-significant-findings","title":"S Modifier: Significant or Potentially Significant Findings","text":"<p>Add \"S\" modifier for clinically significant findings unrelated to lung cancer:</p> <ul> <li>Coronary artery calcification (specify if severe)</li> <li>Emphysema (specify if severe)</li> <li>Interstitial lung abnormalities</li> <li>Infectious/inflammatory conditions requiring treatment</li> </ul> <p>Example: Lung-RADS 2S (benign nodule + severe emphysema)</p>"},{"location":"pulmonary/lung_rads/#c-modifier-previously-known-cancer","title":"C Modifier: Previously Known Cancer","text":"<p>Not used in standard lung cancer screening</p> <p>Reserved for incidental CTs in patients with known cancer.</p>"},{"location":"pulmonary/lung_rads/#comparison-to-prior-exams","title":"Comparison to Prior Exams","text":"<p>New vs Stable vs Growing Nodules</p> <p>Baseline Exam (No Prior):</p> <ul> <li>Classify based on size criteria above</li> </ul> <p>Subsequent Exams (With Prior):</p> <ul> <li>Stable nodule: Remains same category or improves \u2192 Continue as per category</li> <li>New nodule: Not present on prior \u2192 Use \"new nodule\" size criteria</li> <li>Growing nodule: \u22651.5 mm increase in average diameter \u2192 Lung-RADS 4B</li> </ul> <p>Volume Doubling Time (VDT):</p> <ul> <li>VDT &lt;400 days = concerning for malignancy</li> </ul>"},{"location":"pulmonary/lung_rads/#lung-cancer-screening-eligibility","title":"Lung Cancer Screening Eligibility","text":"<p>Who Should Be Screened?</p> <p>USPSTF 2021 Criteria:</p> <ul> <li>Age 50-80 years</li> <li>\u226520 pack-year smoking history</li> <li>Current smoker OR quit within past 15 years</li> <li>No signs/symptoms of lung cancer</li> </ul> <p>Shared Decision-Making Required</p> <p>When to Stop Screening:</p> <ul> <li>Age &gt;80 years</li> <li>Comorbidities limiting life expectancy</li> <li>Patient preference</li> </ul>"},{"location":"pulmonary/lung_rads/#additional-resources","title":"Additional Resources","text":""},{"location":"pulmonary/lung_rads/#institutional-resources","title":"Institutional Resources","text":"<ul> <li>Lung Cancer Screening Program Protocol</li> <li>Shared Decision-Making Tools</li> <li>Patient Education Materials</li> </ul>"},{"location":"pulmonary/lung_rads/#external-links","title":"External Links","text":"<ul> <li>ACR Lung-RADS Official Page</li> <li>USPSTF Lung Cancer Screening Recommendation</li> <li>National Lung Screening Trial (NLST) Results</li> </ul>"},{"location":"pulmonary/lung_rads/#related-guidelines","title":"Related Guidelines","text":"<ul> <li>Fleischner Society 2017 - For incidental nodules</li> <li>NCCN Lung Cancer Screening Guidelines</li> </ul>"},{"location":"pulmonary/lung_rads/#common-pitfalls","title":"Common Pitfalls","text":"<p>Avoid These Mistakes</p> <p>\u274c Don't:</p> <ul> <li>Use Lung-RADS for incidental nodules (use Fleischner instead)</li> <li>Measure nodules in coronal/sagittal only (use axial)</li> <li>Ignore new nodules &lt;4 mm (still report them)</li> <li>Apply to patients outside screening age range</li> </ul> <p>\u2705 Do:</p> <ul> <li>Always compare to prior exams when available</li> <li>Measure solid component of part-solid nodules</li> <li>Document smoking history in report</li> <li>Communicate high-risk findings (4B, 4X) directly to ordering provider</li> </ul>"},{"location":"pulmonary/lung_rads/#version-history","title":"Version History","text":"Date Version Changes 2024-01-15 Internal Initial implementation at institution 2019 v1.1 ACR Lung-RADS 1.1 released 2014 v1.0 Original ACR Lung-RADS published"},{"location":"pulmonary/lung_rads/#references","title":"References","text":"<ol> <li>American College of Radiology. Lung CT Screening Reporting and Data System (Lung-RADS). Version 1.1. 2019.</li> <li>National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365(5):395-409.</li> <li>US Preventive Services Task Force. Screening for Lung Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2021;325(10):962-970.</li> </ol> <p>Last updated: 2024-01-15 | Maintained by: Radiology QI Committee | Contact: radiology_qi@institution.edu</p>"},{"location":"thyroid/thyroid_nodule/","title":"Thyroid Nodule","text":"<p>Original Guideline</p> <p>:octicons-file-pdf-24: Download Original PDF</p>"},{"location":"thyroid/thyroid_nodule/#reference-images","title":"Reference Images","text":""},{"location":"thyroid/thyroid_nodule_us/","title":"Thyroid Nodule US","text":"<p>Original Guideline</p> <p>:octicons-file-pdf-24: Download Original PDF</p>"},{"location":"thyroid/thyroid_nodule_us/#reference-images","title":"Reference Images","text":""},{"location":"thyroid/tirads/","title":"ACR TI-RADS: Thyroid Imaging Reporting and Data System","text":"Reference Information <p>Full Citation: Tessler FN, Middleton WD, Grant EG, et al. ACR Thyroid Imaging, Reporting and Data System (TI-RADS): White Paper of the ACR TI-RADS Committee. J Am Coll Radiol. 2017;14(5):587-595. Version: ACR TI-RADS 2017 Last Institutional Review: January 2024 Modifications: None - following published guidelines exactly  </p>"},{"location":"thyroid/tirads/#quick-reference-tables","title":"Quick Reference Tables","text":"TI-RADS ScoringTI-RADS CategoriesManagement Algorithm Feature Points Description COMPOSITION Cystic or almost completely cystic 0 Anechoic nodule with echogenic wall \u00b1 artifacts Spongiform 0 Aggregation of microcysts &gt;50% of nodule Mixed cystic and solid 1 Any solid component &lt;50% Solid or almost solid 2 Solid component \u226550% ECHOGENICITY Anechoic 0 Simple cyst appearance Hyperechoic or isoechoic 1 Same or brighter than thyroid Hypoechoic 2 Darker than thyroid Very hypoechoic 3 Darker than strap muscles SHAPE Wider-than-tall 0 A-P &lt; transverse diameter Taller-than-wide 3 A-P \u2265 transverse diameter on transverse view MARGIN Smooth 0 Well-defined smooth border Ill-defined 0 Cannot clearly define margin Lobulated or irregular 2 Undulating or jagged contour Extra-thyroidal extension 3 Extends beyond thyroid capsule ECHOGENIC FOCI None or large comet-tail artifacts 0 No foci or V-shaped artifact from colloid Macrocalcifications 1 Large calcific foci with shadowing Peripheral (rim) calcifications 2 Calcifications along nodule margin Punctate echogenic foci 3 Tiny bright spots \u00b1 shadowing/comet-tail Level Points Risk FNA Size Threshold Follow-up Size Threshold Follow-up Interval TR1 0 0.3% No FNA No follow-up None TR2 2 1.5% No FNA No follow-up None TR3 3 4.8% \u22652.5 cm \u22651.5 cm 1, 3, 5 years TR4 4-6 9.1% \u22651.5 cm \u22651.0 cm 1, 2, 3, 5 years TR5 \u22657 35% \u22651.0 cm \u22650.5 cm 1, 2, 3, 5 years TI-RADS Size Recommendation TR1 Any No FNA, no follow-up TR2 Any No FNA, no follow-up TR3 &lt;1.5 cm No FNA, no follow-up TR3 \u22651.5 cm Consider follow-up US at 1, 3, 5 years TR3 \u22652.5 cm Consider FNA TR4 &lt;1.0 cm No FNA, no follow-up TR4 \u22651.0 cm Consider follow-up US at 1, 2, 3, 5 years TR4 \u22651.5 cm Consider FNA TR5 &lt;0.5 cm No FNA, no follow-up TR5 \u22650.5 cm Consider follow-up US at 1, 2, 3, 5 years TR5 \u22651.0 cm FNA recommended"},{"location":"thyroid/tirads/#scoring-instructions","title":"Scoring Instructions","text":"<ul> <li> <p>How to Score</p> <ul> <li>Evaluate all five categories</li> <li>Assign points for each feature</li> <li>Sum total points</li> <li>Determine TI-RADS level</li> <li>Apply size-based recommendations</li> </ul> </li> <li> <p>Key Principles</p> <ul> <li>Score the most suspicious features</li> <li>If multiple features in one category, choose highest points</li> <li>Measure maximum diameter in any plane</li> <li>Consider clinical context</li> </ul> </li> </ul> Measurement Guidelines <p>Size Measurement:</p> <ul> <li>Use maximum diameter in any plane</li> <li>Measure in centimeters (to one decimal)</li> <li>Include solid and cystic components</li> </ul> <p>Important Notes:</p> <ul> <li>Benign features (TR1-TR2): No size threshold</li> <li>Always measure at largest diameter</li> <li>Document plane of measurement</li> </ul> <p>Growth Assessment:</p> <ul> <li>Significant growth: &gt;20% in two dimensions AND &gt;2mm</li> <li>Minimum interval: 6 months</li> <li>Use same measurement technique</li> </ul>"},{"location":"thyroid/tirads/#special-considerations","title":"Special Considerations","text":"<p>When NOT to Use TI-RADS</p> <p>Do NOT apply TI-RADS to:</p> <ul> <li>Nodules in patients &lt;14 years old</li> <li>Nodules with known history of thyroid cancer</li> <li>Lymph nodes</li> <li>Nodules already biopsied or with known cytology</li> <li>Purely cystic nodules (TR1)</li> </ul> <p>Clinical correlation required for:</p> <ul> <li>Rapidly growing nodules</li> <li>Symptomatic nodules (hoarseness, dysphagia)</li> <li>Suspicious lymphadenopathy</li> <li>Elevated thyroglobulin</li> <li>PET-avid nodules</li> </ul> Reporting Tips <p>Structured Report Should Include:</p> <ul> <li>Overall thyroid size and echogenicity</li> <li>Number of nodules</li> <li>For each nodule requiring characterization:<ul> <li>Location (lobe, upper/mid/lower)</li> <li>Size (3 dimensions)</li> <li>Composition (points)</li> <li>Echogenicity (points)</li> <li>Shape (points)</li> <li>Margin (points)</li> <li>Echogenic foci (points)</li> <li>Total TI-RADS points and level</li> <li>Recommendation based on size and TR level</li> </ul> </li> </ul> <p>Example Template:</p> <pre><code>Right mid lobe nodule measures 1.8 x 1.2 x 1.5 cm:\n- Solid composition (2 points)\n- Hypoechoic (2 points)\n- Wider-than-tall (0 points)\n- Irregular margin (2 points)\n- Punctate echogenic foci (3 points)\nTotal: 9 points = TR5\n\nRecommendation: FNA is recommended.\n</code></pre>"},{"location":"thyroid/tirads/#common-pitfalls","title":"Common Pitfalls","text":"<p>Avoid These Errors</p> <p>Scoring Errors:</p> <ul> <li>Don't add multiple features from same category</li> <li>Don't upgrade based on size alone</li> <li>Don't confuse macrocalcifications with punctate foci</li> </ul> <p>Measurement Errors:</p> <ul> <li>Don't include halo in measurement</li> <li>Don't measure only transverse plane</li> <li>Don't round up aggressively</li> </ul> <p>Management Errors:</p> <ul> <li>Don't FNA nodules below size threshold</li> <li>Don't ignore clinical context</li> <li>Don't apply to cervical lymph nodes</li> </ul>"},{"location":"thyroid/tirads/#related-content","title":"Related Content","text":""},{"location":"thyroid/tirads/#related-protocols","title":"Related Protocols","text":"<ul> <li>Thyroid Ultrasound Protocol</li> <li>Thyroid FNA Technique</li> </ul>"},{"location":"thyroid/tirads/#related-guidelines","title":"Related Guidelines","text":"<ul> <li>ATA Thyroid Nodule Management Guidelines</li> <li>Bethesda Classification for Thyroid Cytology</li> <li>EU-TIRADS (European variant)</li> <li>K-TIRADS (Korean variant)</li> </ul>"},{"location":"thyroid/tirads/#external-resources","title":"External Resources","text":"<ul> <li>ACR TI-RADS White Paper</li> <li>ACR TI-RADS Calculator</li> <li>TI-RADS Lexicon Atlas</li> </ul>"},{"location":"thyroid/tirads/#visual-reference-guide","title":"Visual Reference Guide","text":"Image Examples by Category <p>Composition:</p> <ul> <li>Cystic: Anechoic with posterior enhancement</li> <li>Spongiform: Swiss cheese appearance</li> <li>Mixed: Both cystic and solid areas</li> <li>Solid: Uniformly solid tissue</li> </ul> <p>Echogenicity:</p> <ul> <li>Compare to normal thyroid parenchyma</li> <li>Very hypoechoic: Compare to strap muscles</li> </ul> <p>Shape:</p> <ul> <li>Measure A-P and transverse on same image</li> <li>Taller-than-wide seen on transverse view</li> </ul> <p>Margin:</p> <ul> <li>Smooth: Regular border</li> <li>Lobulated: 3+ undulations</li> <li>ETE: Disruption of thyroid capsule</li> </ul> <p>Echogenic Foci:</p> <ul> <li>Comet-tail: V-shaped artifact (benign)</li> <li>Macrocalc: &gt;1mm with shadowing</li> <li>Rim calc: Peripheral eggshell pattern</li> <li>Punctate: Microcalcifications, may shadow</li> </ul>"}]}